Cardiorespiratory Events After Monoclonal Antibody Prophylaxis With Palivizumab

Pediatr Infect Dis J. 2018 Nov;37(11):e281-e282. doi: 10.1097/INF.0000000000002017.

Authors

Tobias Tenenbaum¹, Ursula Drechsel-Bäuerle, Doris Oberle

Affiliation

¹ Pediatric Infectious Diseases and Pulmonology, University Children's Hospital Mannheim, Heidelberg University, Mannheim, Germany Department Safety of Medicinal Products and Medical Devices, Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Institut, Langen, Germany.

PMID: 30308606
DOI: 10.1097/INF.0000000000002017

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal
Gestational Age
Humans
Immunization
Infant
Infant, Newborn
Infant, Premature*
Palivizumab
Respiratory Syncytial Virus Infections*

Substances

Antibodies, Monoclonal
Palivizumab